JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacene, H. A.
Right arrow Articles by Wahl, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacene, H. A.
Right arrow Articles by Wahl, R. L.

Effects of Pegfilgrastim on Normal Biodistribution of 18F-FDG: Preclinical and Clinical Studies

Heather A. Jacene1, Takayoshi Ishimori1, James M. Engles1, Sophie Leboulleux1, Vered Stearns2 and Richard L. Wahl1

1 Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland; and 2 Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland


Figure 1
View larger version (25K):

[in a new window]
  		FIGURE 1.  18F-FDG activity in tissues of rats. Values are mean ± SD (n = 3 rats per group). (A) At 24 h after injection, 18F-FDG activity is higher in bone marrow and lower in blood and kidneys in pegfilgrastim group (*P < 0.05). (B) At 7 d after injection, 18F-FDG uptake is lower in bone marrow and liver and higher in muscle in pegfilgrastim group (*P < 0.05).

 

Figure 2
View larger version (10K):

[in a new window]
  		FIGURE 2.  18F-FDG activity in bone marrow of rats vs. time. Values are mean ± SD (n = 3 rats per group at each time point). Bone marrow 18F-FDG activity was higher (*P < 0.05) in rats 24 h after pegfilgrastim injection. This increase was not observed after injection of saline.

 

Figure 3
View larger version (26K):

[in a new window]
  		FIGURE 3.  18F-FDG uptake in bone marrow (A) and spleen (B) in patients (n = 16) at baseline and after single doses of adjuvant pegfilgrastim (scan 2). Average SULmean in bone marrow and spleen is significantly higher on scan 2 (P < 0.0001).

 

Figure 4
View larger version (99K):

[in a new window]
  		FIGURE 4.  Maximum-intensity-projection images at baseline (A) and after single doses of docetaxel and pegfilgrastim (B) in patient 9. Diffusely increased 18F-FDG activity is seen in bone marrow (arrowhead) and spleen (curved arrow) on scan 2. Multifocal right breast cancer has intense 18F-FDG activity on both scans; however, activity appears less intense on scan 2 (straight arrows). Physiologic 18F-FDG activity is seen in brain, kidneys, bladder, liver, and colon.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.